Bank Of New York Mellon Corp Kronos Bio, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.44 - $3.44 $192,206 - $459,160	133,477 New	133,477 $216,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $37,834 - $62,681	11,294 Added 9.24%	133,537 $447,000
Q2 2022 Aug 15, 2022	SELL	$3.12 - $7.52 $34,788 - $83,848	-11,150 Reduced 8.36%	122,243 $445,000
Q1 2022 May 11, 2022	SELL	$6.26 - $14.42 $29,678 - $68,365	-4,741 Reduced 3.43%	133,393 $965,000
Q4 2021 Feb 11, 2022	BUY	$11.35 - $21.18 $29,510 - $55,068	2,600 Added 1.92%	138,134 $1.88 Million
Q3 2021 Nov 12, 2021	BUY	$18.17 - $24.7 $402,992 - $547,821	22,179 Added 19.57%	135,534 $2.84 Million
Q2 2021 Aug 11, 2021	BUY	$20.08 - $29.02 $1.5 Million - $2.17 Million	74,750 Added 193.63%	113,355 $2.71 Million
Q1 2021 May 13, 2021	BUY	$27.0 - $32.48 $33,426 - $40,210	1,238 Added 3.31%	38,605 $1.13 Million
Q4 2020 Feb 09, 2021	BUY	$26.68 - $38.23 $996,951 - $1.43 Million	37,367 New	37,367 $1.12 Million

20.7M

31.4K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $55.1M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.